Ann: Letter to Shareholders, page-2

Unfortunately some of the language in the letter and in recent prelim announcements has not been as upbeat as 2018. MM has now admitted there are currently no validated assays that allow measurement of decreased reservoirs to be done in an accurate and meaningful way... meaning there may never be a way to determine if in fact BIT225 is clearing them entirely. A lot of $$ and time spent on recent trials which tell us not a lot more than what we already knew.... with no commercial deal forthcoming.

Also the comment "Biotron’s portfolio extends beyond BIT225." is kind of telling us this drug maybe dead in the water from a commercial aspect, while also telling us "Company remains wholly focused on doing all it can to achieve a commercial outcome to benefit shareholders." I wouldn't trust these guys to be getting out of bed everyday let alone deliver any commercial benefits to shareholders.

No mention whatsoever of future funding and COVID results... not wanting to communicate on what really matters to shareholders at this point in time is not good enough.